628 related articles for article (PubMed ID: 27448818)
1. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
2. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
3. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset.
Wang L
Tumour Biol; 2013 Jun; 34(3):1679-84. PubMed ID: 23532688
[TBL] [Abstract][Full Text] [Related]
5. Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays.
Hass HG; Vogel U; Scheurlen M; Jobst J
Gut Liver; 2018 May; 12(3):306-315. PubMed ID: 29271183
[TBL] [Abstract][Full Text] [Related]
6. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
7. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma.
Jiang Y; Zheng X; Jiao D; Chen P; Xu Y; Wei H; Qian Y
EBioMedicine; 2019 Feb; 40():422-431. PubMed ID: 30638862
[TBL] [Abstract][Full Text] [Related]
8. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
Xue TC; Zhang BH; Ye SL; Ren ZG
Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
[TBL] [Abstract][Full Text] [Related]
9. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
10. Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis.
Li L; Lei Q; Zhang S; Kong L; Qin B
Oncol Rep; 2017 Nov; 38(5):2607-2618. PubMed ID: 28901457
[TBL] [Abstract][Full Text] [Related]
11. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors.
Burenina OY; Lazarevich NL; Kustova IF; Shavochkina DA; Moroz EA; Kudashkin NE; Patyutko YI; Metelin AV; Kim EF; Skvortsov DA; Zatsepin TS; Rubtsova MP; Dontsova OA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):49-59. PubMed ID: 32918630
[TBL] [Abstract][Full Text] [Related]
12. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.
Huang QX; Cui JY; Ma H; Jia XM; Huang FL; Jiang LX
Cancer Gene Ther; 2016; 23(2-3):48-53. PubMed ID: 26679756
[TBL] [Abstract][Full Text] [Related]
13. A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies.
Wang F; Wang R; Li Q; Qu X; Hao Y; Yang J; Zhao H; Wang Q; Li G; Zhang F; Zhang H; Zhou X; Peng X; Bian Y; Xiao W
Diagn Pathol; 2017 Jan; 12(1):4. PubMed ID: 28086821
[TBL] [Abstract][Full Text] [Related]
14. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive circular RNA expression profiling constructs a ceRNA network and identifies hsa_circ_0000673 as a novel oncogene in distal cholangiocarcinoma.
Zhao X; Zhang X; Zhang Z; Liu Z; Zhu J; Lyu S; Li L; Lang R; He Q
Aging (Albany NY); 2020 Nov; 12(22):23251-23274. PubMed ID: 33221765
[TBL] [Abstract][Full Text] [Related]
16. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
Gene; 2019 May; 698():9-18. PubMed ID: 30825595
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma.
Li H; Long J; Xie F; Kang K; Shi Y; Xu W; Wu X; Lin J; Xu H; Du S; Xu Y; Zhao H; Zheng Y; Gu J
Oncol Rep; 2019 Nov; 42(5):1833-1842. PubMed ID: 31545466
[TBL] [Abstract][Full Text] [Related]
19. Identification of Hepatocellular Carcinoma-Related Potential Genes and Pathways Through Bioinformatic-Based Analyses.
Wan Z; Zhang X; Luo Y; Zhao B
Genet Test Mol Biomarkers; 2019 Nov; 23(11):766-777. PubMed ID: 31633428
[No Abstract] [Full Text] [Related]
20. Dysregulation of microRNA in cholangiocarcinoma identified through a meta-analysis of microRNA profiling.
Likhitrattanapisal S; Kumkate S; Ajawatanawong P; Wongprasert K; Tohtong R; Janvilisri T
World J Gastroenterol; 2020 Aug; 26(29):4356-4371. PubMed ID: 32848339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
